DermRx.

This week

Weekly LLM-curated digest of pipeline moves, readouts, guideline changes, and the prompts that generate them.

Weekly briefAdd data
Last ingest run: 2026-08-16 · 19 new entries from week of 2026-08-10

What's new

Week of 2026-08-10 · 19 changes from ingest

New trials (19)

  • NCT07758075 (PHASE2) — A Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Inject
  • NCT07765628 (PHASE2) — A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant W
  • NCT07765888 (PHASE3) — A Study to Learn About the Study Medicine Called Tilrekimig in People With Moder
  • NCT07754968 (NA) — Use of Bifidobacterium Bifidum in Formula-Fed Infants With Colic, With or Withou
  • NCT07754786 (PHASE3) — A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Partic
  • NCT07762833 (PHASE3) — Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Sub
  • NCT07757867 (NA) — Microneedling-Assisted Delivery of Cetirizine Versus Latanoprost in Alopecia Are
  • NCT07758400 (NA) — A Study on the Efficacy and Safety of Microneedling for Male Androgenetic Alopec
  • NCT07762443 (PHASE1) — A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Are
  • NCT07763262 (NA) — Autologous Nanofat Injection for Treatment of Stable Vitiligo
  • NCT07755670 — Exploration of Brain Functional Networks in Patients With Hidradenitis Suppurati
  • NCT07756346 (PHASE2) — A Study to Evaluate the Efficacy of Botulinum Toxin in Patients With Hidradeniti
  • NCT07766005 (PHASE2) — A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (Th
  • NCT07756957 (PHASE2) — Safety of the Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Modera
  • NCT07759505 — Efficacy and Tolerability Evaluation of a Novel Dermo-cosmetic Product for Mild-
  • NCT07753811 (NA) — Effect of Oral Isotretinoin on Ocular Surface and Meibomian Glands
  • NCT07765979 (NA) — Mediterranean and Low-Histamine Diets for Pediatric Chronic Spontaneous Urticari
  • NCT07764003 (PHASE2) — A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Re
  • NCT07766499 (PHASE2) — A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multice

Earlier ingest runs

Week of 2026-08-0318 changes · 18 trials
Week of 2026-07-2724 changes · 24 trials
Week of 2026-07-1316 changes · 16 trials
Week of 2026-07-0615 changes · 15 trials
Week of 2026-06-297 changes · 7 trials
Week of 2026-06-2214 changes · 14 trials
Week of 2026-06-157 changes · 7 trials
Week of 2026-06-0812 changes · 12 trials
Week of 2026-06-0111 changes · 11 trials
Week of 2026-05-257 changes · 7 trials
Week of 2026-05-1813 changes · 13 trials
Week of 2026-05-1111 changes · 1 approvals · 1 ingredients · 9 trials
Week of 2026-05-047 changes · 7 trials
Week of 2026-04-2714 changes · 14 trials
Week of 2026-04-205527 changes · 68 approvals · 33 ingredients · 5422 trials · 4 MOA
Week of 2026-04-131417 changes · 132 approvals · 121 ingredients · 1150 trials · 14 MOA

2026-W16

source: gemini

This weekly brief summarizes key regulatory, clinical, and guideline developments in the fields of psoriasis and atopic dermatitis (AD) for the period of April 1, 2026, to April 17, 2026.

Approvals

Anzupgo (delgocitinib) cream — FDA sNDA Acceptance · April 15, 2026 Source: leo-pharma.com/media-center/news/2026-acceptance-of-anzupgo-snda Why it matters: If approved, this topical pan-JAK inhibitor would be the first indicated treatment specifically for pediatric patients (ages 12–17) with moderate-to-severe chronic hand eczema (CHE).

Icotyde (icotrokinra) — Commercial Launch/Update · April 7, 2026 Source: fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026 Why it matters: Following its mid-March approval, new 1-year data confirmed its position as the first targeted oral peptide for IL-23 receptor antagonism, offering biologic-like efficacy in a daily pill for plaque psoriasis.

Trial readouts

Zasocitinib — Phase 3 LATITUDE results (Full Data) · April 7, 2026 Source: clinicaltrials.gov/study/NCT06671483 / hcplive.com/view/6-dermatology-headlines-you-missed-march-2026 Why it matters: Demonstrated superiority over placebo and apremilast in moderate-to-severe psoriasis, with nearly 30% of patients achieving PASI 100 at week 16, reinforcing the strength of the next-gen TYK2 inhibitor pipeline.

Rademikibart — Phase 3 RADIANT-AD 52-week data · April 7, 2026 Source: hcplive.com/view/6-dermatology-headlines-you-missed-march-2026 Why it matters: Long-term data showed sustained near-maximal skin clearance and pruritus control through one year, establishing it as a highly durable IL-4Rα antagonist competitor.

Guideline / safety updates

AAD 2026 Guidelines: Management of Atopic Dermatitis in Pediatric Patients — Publication · April 7, 2026 Source: jaad.org/article/S0190-9622(26)00113-X/fulltext Why it matters: The first pediatric-specific AD guidelines from the AAD, granting "Strong" evidence-based recommendations for aryl hydrocarbon receptor (AhR) agonists like tapinarof in children as young as 2 years old.

International Eczema Council (IEC) Consensus Statement — JAMA Dermatology · April 15, 2026 Source: jamanetwork.com/journals/jamadermatology/fullarticle/2816625 Why it matters: Standardizes the definitions for "Low Disease Activity" and "Remission" in AD, providing essential benchmarks for clinical trial design and "treat-to-target" strategies in routine practice.